Biotech News

Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights

Scholar Rock (SRRK)Scholar Rock2026-06-25 13:46 ESTFDA / regulatory

FDA accepted apitegromab Biologics License Application (BLA) for treatment of children and adults with spinal muscular atrophy (SMA) with September 30, 2026 Prescription Drug User Fee Act (PDUFA) action date Accepted apitegromab BLA includes two fill-finish facilities, Catalent Indiana LLC (part of

Open original release

Related news

SRRKScholar Rock2026-06-25 13:46 EST

Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD

SRRKScholar Rock2026-06-25 13:46 EST

Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

SRRKScholar Rock2026-06-25 13:46 EST

Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference

SRRKScholar Rock2026-06-25 13:46 EST

Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

SRRKScholar Rock2026-06-25 13:46 EST

Scholar Rock to Present at Upcoming Investor Conferences

SRRKScholar Rock2026-06-25 13:46 EST

Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

SRRKScholar Rock2026-06-25 13:46 EST

CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

SRRKScholar Rock2026-06-25 13:46 EST

Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

SRRKScholar Rock2026-06-25 13:46 EST

Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026

SRRKScholar Rock2026-06-25 13:46 EST

Scholar Rock to Present at the BofA Securities 2026 Health Care Conference

View all latest news

Scholar Rock

Scholar Rock is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

SRRKScholar Rock2026-06-26 10:02 EST

Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD

SRRKScholar Rock2026-06-26 10:02 EST

Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

SRRKScholar Rock2026-06-26 10:02 EST

Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference

SRRKScholar Rock2026-06-26 10:02 EST

Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights

SRRKScholar Rock2026-06-26 10:02 EST

Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States